Commercial Channels

Consulting and marketing research firm breaks down product brand identity

Business, regulatory and technological conditions are constantly changing. Will your CRM/SFA system be flexible enough to keep up?

Multi-tenant sales-force automation (SFA) systems are coping with an increasingly complex regulatory environment

PhRMA pushes for an FDA ‘universal symbol’ of approved content, and seeks latitude in communications in online forums

The Medical Affairs function can play a vital role in today’s product launch process

Over half of all physicians are participating in social-media sites or online professional networks

While researchers study new pain-killing pathways, the pharma industry tries drug combinations and alternative-delivery mechanisms By Angelo DePalma, PhD

In competing for pharmacy business, AmerisourceBergen, Cardinal Health and McKesson offer improved access to branded and generic products

FDA’s requirements for risk evaluation and mitigation challenge both new and existing commercialization processes

The current FDA policy toward REMS is being challenged by Allergan

The basic process of defining customer segments and appropriate promotional messaging benefits from a cross-disciplinary approach

MarkMonitor sees 23% growth in offshore business exchanges for bulk pharmaceuticals and APIs

Tried-and-true consumer-marketing techniques help product launches, patient adherence programs

‘Managed Market Delegates on Demand’ is one; ‘Ask IMS’ is another; meanwhile, online communities offer on-demand access

LOOKING AHEAD . . .

2009 PDMA SHARING CONFERENCE EXHIBITORS

Health Mart franchise network is now over 2,300 independent pharmacies

Purchase adds mobile content delivery to PI’s slate of communications services

Five steps to take when the duty for developing Risk Evaluation and Mitigation Strategies (REMS) is imposed on commercial operations

Evidence Generation Is the Foundation to Optimal Product Positioning

A 3.8% CAGR will rise to 8.0% for 2009-2013, says Kalorama Information

Medical and economic results from Diabetes Ten City Challenge show significant benefits in patient health, lower healthcare costs—and higher pharmaceutical usage

Spurred by some recent successful launches, and with hefty R&D funding commitments, the vaccine business is booming

Evaluating medicine and healthcare by their outcomes is now an NIH priority